FibroBiologics Stock (NASDAQ:FBLG)

Forecast Ownership Financials Chart

Previous Close

$1.02

52W Range

$0.62 - $9.60

50D Avg

$1.33

200D Avg

$2.53

Market Cap

$6.33M

Avg Vol (3M)

$217.89K

Beta

1.22

Div Yield

FBLG Company Profile

FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Feb 01, 2024

Website

FBLG Performance

FBLG Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-16.65M	$-13.74M	$-8.89M
Net Income	$-18.65M	$-11.16M	$-16.48M
EBITDA	$-16.65M	$-10.57M	$-15.90M
Basic EPS	$-0.42	$-0.34	$-0.59
Diluted EPS	$-0.42	$-0.34	$-0.59

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
DARE	Dare Bioscience, Inc.
ICU	SeaStar Medical Holding Corporation
AIMD	Ainos, Inc.
CTXR	Citius Pharmaceuticals, Inc.
MBRX	Moleculin Biotech, Inc.
APLM	Apollomics, Inc.
ATHA	Athira Pharma, Inc.
ADTX	Aditxt, Inc.
LPTX	Leap Therapeutics, Inc.